ReviewClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2014
The role of vaccination in preventing pneumococcal disease in adults.
Review in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Prevalence ofHuman vaccines & immunotherapeutics · 2024Pooled it
- A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly.Human vaccines & immunotherapeutics · 2019Trial
- Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis.Clinical and vaccine immunology : CVI · 2016Trial
- Influenza A Virus Coinfection AltersbioRxiv : the preprint server for biology · 2026Article
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Recommendations on PCV20 vaccine in adults and at-risk populations.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Article
- Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.Microorganisms · 2024Review
- Macrophages and the microbiome in chronic obstructive pulmonary disease.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Review
- Emerging vaccine strategies against the incessant pneumococcal disease.NPJ vaccines · 2023Review
- Emerging pneumococcal serotypes in Iraq: scope for improved vaccine development.F1000Research · 2023Review
- Uptake of pneumococcal vaccination in older people in northern Israel.Preventive medicine reports · 2021Article
- Vaccines and Senior Travellers.Frontiers in aging · 2021Review
- Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis.Human vaccines & immunotherapeutics · 2018Article
- Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Human vaccines & immunotherapeutics · 2018Review
- Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.Risk management and healthcare policy · 2018Review
- Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them.Human vaccines & immunotherapeutics · 2018Review
- Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy.Therapeutic advances in respiratory disease · 2017Observational
- Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.Respiratory research · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Pneumococcal infections, including pneumonia and invasive disease, are major sources of morbidity and mortality worldwide. Prevention of the first acquisition of Streptococcus pneumoniae through the use of vaccines represents an effective method to reduce the burden of the disease in both children and adults. Two vaccines are currently available in adults: a pneumococcal polysaccharide vaccine (PPV23) that includes 23 purified capsular polysaccharide antigens and a pneumococcal protein-conjugate vaccine (PCV13) that includes capsular polysaccharide antigens covalently linked to a non-toxic protein. The PPV23 induces a humoral immune response and since it has been licensed has been the subject of debates and controversies. Numerous studies and meta-analyses have shown that PPV23 protects against invasive pneumococcal disease, although there are conflicting data regarding its efficacy for the prevention of pneumonia. Vaccination with PCV13 stimulates good antibody responses as well as mucosal immunity and suppresses colonization. A conjugate vaccine can be expected to have benefits over a polysaccharide vaccine because of the characteristics of a T-cell-dependent response in terms of affinity, maturation of antibodies with repeated exposure, induction of immunological memory and long-lasting immunity. PCV13 has demonstrated all of these characteristics in children and fundamental differences in adults are not expected. The efficacy in adults is currently being investigated and results will be available soon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.